Atıf İçin Kopyala
Ercan S., Ergan B., ÖZUYGUR ERMİŞ S. S., Korkmaz P., Tasbakan M. S., Basoglu O. K., ...Daha Fazla
TURKISH THORACIC JOURNAL, cilt.23, sa.3, ss.225-230, 2022 (ESCI)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
23
Sayı:
3
-
Basım Tarihi:
2022
-
Doi Numarası:
10.5152/turkthoracj.2022.21179
-
Dergi Adı:
TURKISH THORACIC JOURNAL
-
Derginin Tarandığı İndeksler:
Emerging Sources Citation Index (ESCI)
-
Sayfa Sayıları:
ss.225-230
-
Anahtar Kelimeler:
Tocilizumab, COVID-19, mortality, biomarkers, CALL score, COVID-19
-
Dokuz Eylül Üniversitesi Adresli:
Evet
Özet
OBJECTIVE: A substantial number of patients with coronavirus disease-2019 (COVID-19) demonstrate severe infection. Cytokine storm is an underlying condition that worsens clinical outcomes. As an interleukin-6 receptor antagonist, tocilizumab is a promising treatment option for COVID-19. This study aimed to evaluate the clinical predictors of mortality for critically ill COVID-19 patients receiving tocilizumab therapy.